SIRPA and neoplasm: Overall, our results suggest that the combination of NextA and anti-SIRPα does not provide an additive effect to reduce tumor growth of SM1 melanoma, potentially due to the downregulation of SIRPα on macrophages by NextA, which might decrease the efficacy of anti-SIRPα.